Orforglipron
vs Retatrutide.
Compare FDA-approved Foundayo orforglipron with investigational retatrutide by non-peptide versus peptide identity, route, mechanism, trial results, and status.
Also searched as Foundayo vs Retatrutide · oral GLP-1 pill vs triple-agonist peptide
Orforglipron vs Retatrutide: What is the difference?
Orforglipron and retatrutide both engage the GLP-1 receptor, but they are fundamentally different drugs with no head-to-head trial. Orforglipron is a non-peptide small molecule and the active ingredient in the FDA-approved oral product FOUNDAYO. Retatrutide is an investigational synthetic peptide that activates GIP, GLP-1, and glucagon receptors and is being studied as a weekly injection. FOUNDAYO has an approved US label and pharmacy product record. Retatrutide has Phase 3 obesity results but no marketing approval. The larger retatrutide percentage came from a different trial, duration, regimen, and estimand, so it cannot establish superiority over orforglipron.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Orforglipron
FDA-approved prescription drug
- Route
- Oral
- Registry
- Dedicated medicine evidence record
- Sponsor
- Lilly USA, LLC
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
Orforglipron vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between Orforglipron and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Orforglipron
Non-peptide small-molecule GLP-1 receptor agonist
- Route
- Oral
- Stage
- NDA 220934 approved product record
- Status
- FDA-approved prescription drug
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Orforglipron
Non-peptide small-molecule GLP-1 receptor agonist
- Route
- Oral
- Stage
- NDA 220934 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 220934
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
This comparison resolves three fast-growing search questions at once: whether orforglipron is a peptide, whether an approved oral medicine can be compared with a late-stage injection, and whether the largest percentage names the better drug. The evidence can answer molecular class, receptor strategy, route, approval, trial population, duration, estimand, and product availability. It cannot predict an individual result or replace a direct randomized comparison.
| Field | Orforglipron | Retatrutide | How to interpret it |
|---|---|---|---|
| Molecular identity | Non-peptide small-molecule GLP-1 receptor agonist | Synthetic peptide triple agonist | A shared GLP-1 receptor target does not make orforglipron a peptide or make the molecules pharmacologically interchangeable. |
| Receptor strategy | GLP-1 receptor agonism | GIP, GLP-1, and glucagon receptor agonism | Receptor count and mechanism can describe the programs but cannot determine comparative benefit, safety, or suitability on their own. |
| Route and product | FOUNDAYO oral tablets under NDA 220934 | Once-weekly subcutaneous injection under clinical investigation | One has an exact approved US product record while the other remains a sponsor-controlled clinical program without a retail product. |
| Weight evidence anchor | 11.2% at 72 weeks under the ATTAIN-1 treatment-regimen estimand | 28.3% at 80 weeks under the TRIUMPH-1 efficacy estimand | Different trials, estimands, durations, doses, populations, and placebo responses prevent a valid numerical winner claim. |
| Current US status | FDA approved April 1, 2026 for a defined adult weight-management population | Investigational Phase 3 program with no FDA approval | Approval status answers current access and labeling, not which mechanism would produce a better outcome for an individual. |
Why the headline numbers do not name a winner.
ATTAIN-1 reported an 11.2% mean reduction at 72 weeks for the highest studied orforglipron group under the treatment-regimen estimand, versus 2.1% with placebo. TRIUMPH-1 reported 28.3% at 80 weeks for the highest retatrutide group under an efficacy estimand and 25.0% under a treatment-regimen estimand. The studies did not share randomization, molecule class, receptor strategy, approved formulation, escalation plan, population, placebo response, or missing-data handling. Subtracting the percentages would create a comparison the trials did not test.
Keep the comparison honest.
- 01
Keep the molecule classes explicit: orforglipron is a non-peptide small molecule, while retatrutide is a peptide-based triple-agonist program.
- 02
Attach every percentage to its protocol, duration, population, dose strategy, placebo response, and estimand instead of subtracting unrelated trial averages.
- 03
Treat FOUNDAYO as an exact approved US product and retatrutide as investigational, while rejecting any online item that borrows either evidence record by name alone.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →